SPOTLIGHT: Merck profits jump by 62 percent

Merck & Co. saw its profits soar by 62 percent to $1.53 billion, on a 12 percent jump in revenue and lower admin and overhead costs; Singulair was the big seller for the quarter at $1 billion. Release

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.